AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02519881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: simple microfracture of ankle
Study NCT02519881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: simple microfracture of ankle
Study NCT02519881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CartiFill
Description: add collagen when doing microfracture
Study NCT01587742 — intervention group
Intervention type: DRUG
Intervention: CCB use
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
Study NCT02914509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost
Study NCT02914509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study NCT00552110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)
Description: MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
Study NCT00552110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)
Description: MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
Study NCT04176094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16h overnight duty
Description: schedule observed by participating ICUs.
Study NCT00552110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray (MFNS) once daily
Description: MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
Study NCT00552110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxymetazoline nasal spray (OXY) twice daily
Description: OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
Study NCT00552110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MFNS given every morning and every evening x 2 weeks.
Study NCT03602560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar 5-10 mg
Description: Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
Study NCT00427856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Description: Obatoclax mesylate 40mg, and 60mg
Study NCT00427856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab
Study NCT02096094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardization phase
Description: Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
Study NCT02096094 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardization phase
Description: Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
Study NCT02096094 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control bath
Description: Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
Study NCT04176094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24h overnight duty
Description: schedule observed by participating ICUs.
Study NCT04176094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handover training
Description: Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
Study NCT04176094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handover training
Description: Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
Study NCT01695720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VisionScope Imaging (VSI) Exam
Description: The VisionScope Imaging (VSI) Exam \[the system itself\] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
Study NCT01469026 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT or Conventional diagnostics including CT
Description: Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml).
Study NCT01561807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-787
Study NCT01561807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03148808 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NVS Therapy
Description: Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
Study NCT03549364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Race
Description: 1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
Study NCT01307722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left atrial distensibility-guiding prescription of heart failure drugs
Description: This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
Study NCT01889719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-CMDR
Description: injections of MVA-CMDR vaccine
Study NCT01889719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-CMDR
Description: injections of MVA-CMDR vaccine
Study NCT00627419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
Study NCT03048812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O'Ring Attachment (A)
Description: Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
Study NCT03048812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equator Attachment (B)
Description: Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
Study NCT03600376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ryanodex and Standard of Care
Description: Ryanodex to be administered as a rapid IV push
Study NCT03600376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Body cooling measures and supportive measures
Study NCT00415363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until disease progression
Study NCT00415363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study NCT00424047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013 plus dexamethasone
Description: 25 mg daily for 21 days every 28 days.
Study NCT00424047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus Placebo
Description: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
Study NCT02134834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP0595
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Study NCT02134834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
Study NCT04184518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Cediranib 20mg, oral, 5 days on and 2 days off until disease progression
Study NCT04184518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg, intravenous, every 4 weeks until disease progression
Study NCT03863418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: PROBIOTIC
Study NCT03863418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02370719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for diabetes self-management
Study NCT02818842 — intervention group
Intervention type: OTHER
Intervention: Primary Health Insurance Fund data
Description: Data collected are:~* First and last name of mother~* Age~* Mother's date of birth~* Theorical date of beginning of pregnancy~* Childbirth date
Study NCT02818842 — intervention group
Intervention type: OTHER
Intervention: Prenatal Diagnostic Center of Toulouse University Hospital data
Description: Data collected are :~* First and last name of the mother~* Mother's birth date~* Mother Obstetric history~* Course of pregnancy~* Drug exposure (name, decision period)~* Medical termination of pregnancy (date, cause ...)~* Malformations (description, test results, gender of the child,~* Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology).
Study NCT02818842 — intervention group
Intervention type: OTHER
Intervention: Mother and child protection data collection
Description: Date collected are :~* Name and surname of Mother~* Date of birth of the mother~* Obstetric history of the mother (the first certificate to 8 days)~* Course of pregnancy (1st certificate to 8 days)~* Birth data (1 certificate to 8 days)~* Child gender,~* Age of the child at the time of the review,~* Weight, height and head circumference of the child~* American Pediatric Gross Assessment Record (1 certificate to 8 days)~* Neonatal diseases (1 certificate to 8 days)~* Birth defects (1 certificate to 8 days)~* Death (age at death)~* History (certificates at 9 and 24 months)~* Current diseases (certificates at 9 and 24 months)~* Psychomotor development (certificates at 9 and 24 months).~* Date of drugs issue~* Amount of drug issued~* Type of feeding (1 certificate to 8 days)
Study NCT02818842 — intervention group
Intervention type: OTHER
Intervention: Medicalisation Program of Information Systems data
Description: Data collected are :~* First and last name of the mother~* Mother's birth date~* History of abortions (date and cause)
Study NCT01760408 — intervention group
Intervention type: OTHER
Intervention: all patients on Home Parenteral Nutrition
Study NCT03313349 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy: 1. cognitive therapy 2.family intervention
Description: Psychotherapy delivered by trained psychologist for the student and the student´s parents
Study NCT03152981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
Study NCT03152981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
Study NCT03152981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
Study NCT04407806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Pulse oximeter
Description: Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation throughout hospitalization
Study NCT04407806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pulse oximeter
Description: Pulse oximeter is a small lightweight non-invasive device placed on the fingertip or toe to measure blood oxygen saturation intermittently during hospitalization
Study NCT03182114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: supine position
Description: the patient will be placed in regular supine position after spinal anesthesia
Study NCT03182114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left lateral tilted position
Description: the patient will be placed in left lateral tilted position after spinal anesthesia
Study NCT03182114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The patient will receive 10 mg Bupivacaine for spinal anesthesia
Study NCT03182114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: The patient will receive 10 mg Bupivacaine for spinal anesthesia
Study NCT04700254 — intervention group
Intervention type: OTHER
Intervention: DASS questionnaire
Description: The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress
Study NCT04700254 — intervention group
Intervention type: OTHER
Intervention: EAT-26 questionnaire
Description: The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipoplus (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipoplus + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOFlipid (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT03149653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOFlipid + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study NCT02496416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Program
Description: The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
Study NCT02496416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Program
Description: The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
Study NCT03648658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 120Mg/5mL Oral Suspension
Description: The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
Study NCT01037023 — intervention group
Intervention type: DRUG
Intervention: Topotecan
Description: patients administrated Topotecan according to the prescribing information
Study NCT03968796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT03968796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT03968796 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)
Study NCT03968796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Study NCT03602560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar 10 mg
Description: Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
Study NCT03602560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
Study NCT00423787 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ragweed MATA MPL
Description: 4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml